A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Eli Lilly Is Maintained at Overweight by Wells Fargo
Eli Lilly Is Maintained at Buy by Citigroup
Eli Lilly Analyst Ratings
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $997
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Argus Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,020
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,115
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $973
TD Cowen has lowered the Target Price for Eli Lilly and Co to $900.
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $950
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $970
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996